Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA‐REG OUTCOME trial with a focus on Asia

Figures

• 

  FIGURE 1. Effect of empagliflozin on all‐cause mortality, HHF or CV death, and incident/worsening nephropathy by baseline BMI category (WHO) in all participants and participants of Asian race. Data from Cox regression models as described in the Methods section. BMI, body mass index; CI, confidence interval; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HHF, hospitalization for heart failure; HR, hazard ratio; WHO, World Health Organization. †Incidence rate per 1000 patient‐years. ‡HR not calculated as <14 events. §Excluding fatal stroke. ††Progression to macroalbuminuria, doubling of serum creatinine accompanied by eGFR ≤ 45 mL/min/1.73 m2, initiation of renal replacement therapy, or death from renal disease

• 

  FIGURE 2. Effect of empagliflozin on all‐cause mortality, HHF or CV death, and incident/worsening nephropathy in Asian participants by baseline BMI category <24, 24 to <28, or ≥28 kg/m2. Data from Cox regression models as described in the Methods section. BMI, body mass index; CI, confidence interval; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HHF, hospitalization for heart failure; HR, hazard ratio. †Incidence rate per 1000 patient‐years. ‡Excluding fatal stroke. §Progression to macroalbuminuria, doubling of serum creatinine accompanied by eGFR ≤ 45 mL/min/1.73 m2, initiation of renal replacement therapy, or death from renal disease